Shenzhen, China - August 7, 2025 - SeekIn Inc., a leading innovator in liquid biopsy-based cancer diagnostics, proudly announces that its flagship multi-cancer early detection (MCED) product, OncoSeek®, has been formally recognized in the newly released “Expert Consensus on Liquid Biopsy-Based Multi-Cancer Early Detection (2025 Edition)”. This landmark national expert consensus was jointly issued by China’s top oncology and public health authorities, including the Office of Cancer Screening, National Cancer Center and a multidisciplinary expert panel.
The consensus, published in Chinese Journal of Oncology (Vol. 52, No. 12), emphasizes OncoSeek's clinical value as a representative MCED solution based on protein tumor biomarkers. OncoSeek’s inclusion marks a significant milestone in the advancement of accessible, cost-effective cancer screening technologies developed by SeekIn. The article can be found at 10.3760/cma.j.cn112152-20250605-00257.
“OncoSeek demonstrates robust performance in early detection across nine common malignancies,” the consensus states, highlighting the assay’s overall sensitivity of 51.7%, specificity of 92.9%, and early-stage cancer sensitivity (stage I-II) of 49.5%. It also achieved a tumor origin prediction accuracy of 66.8%, supporting its use in guiding follow-up diagnostics.
A Leap Forward for Accessible MCED Screening
OncoSeek® utilizes a panel of seven well-established protein tumor markers (AFP, CEA, CA125, CA15-3, CA19-9, CA72-4, CYFRA21-1), combined with proprietary AI-driven algorithms, to screen for nine major cancer types, including breast, colorectum, liver, lung, lymphoma, esophagus, ovary, pancreas, and stomach.
Unlike genomics-based MCED methods that require advanced sequencing and incur high costs, OncoSeek is designed to be widely deployable, relying on commonly available clinical instruments such as the Roche Cobas system. It is well-suited for use in population-scale cancer screening programs, especially in low- and middle-income countries.
Global Impact and Vision
“This recognition by China’s leading cancer experts validates our commitment to democratizing cancer early detection,” said Dr. Mao Mao, Founder and CEO of SeekIn Inc. “We believe OncoSeek offers an effective, scalable solution to address global disparities in cancer screening, and we are actively expanding access across Asia, the Middle East, Africa, and Latin America.”
SeekIn has already partnered with international NGOs and healthcare institutions to bring OncoSeek to nearly ten countries. With CE-IVD certification obtained in 2022, the company is also engaged in ongoing real-world studies and regulatory submissions worldwide. OncoSeek is now available in Brazil, Bulgaria, China, Colombia, Mexico, the Netherlands, Nigeria, Pakistan, and Poland.